Trial Profile

Phase 1 Ascending Multiple-Dose Study to Evaluate the Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of BMS-906024 in Subjects With Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 31 Jul 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Osugacestat (Primary) ; Dexamethasone
Indications Precursor cell lymphoblastic leukaemia-lymphoma; T-cell lymphoma
Focus Adverse reactions
Sponsors Bristol-Myers Squibb

29 May 2018 Status changed from active, no longer recruiting to completed.
30 Jan 2018 Planned End Date changed from 29 Jun 2018 to 1 Jul 2018.
30 Jan 2018 Planned primary completion date changed from 29 Jun 2018 to 28 Jun 2018.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com